National Institute for Health and Care Excellence. (2021) Cannabis-based medicinal products. London: NICE. NICE guideline [NG144].
Preview | Title | Contact |
---|---|---|
|
PDF (Cannabis-based medicinal products - guidance. November 2019)
134kB | |
|
PDF (Cannabis-based medicinal products: clarification of guidance - March 2021)
- Supplemental Material
48kB |
External website: https://www.nice.org.uk/guidance/NG144
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Recommendations
This guideline includes recommendations on:
- Intractable nausea and vomiting
- Chronic pain
- Spasticity
- Severe treatment-resistant epilepsy
- Prescribing
Products covered by the guideline include:
- cannabis-based products for medicinal use as set out by the UK Government in the 2018 Regulations
- the licensed products delta-9-tetrahydrocannibinol combined with cannabidiol (Sativex) and nabilone
- plant-derived cannabinoids such as pure cannabidiol (CBD)
- synthetic compounds which are identical in structure to naturally occurring cannabinoids such as delta-9-tetrahydrocannabinol (THC), for example, dronabinol.
B Substances > Cannabis product (Cannabinoids) > Cannabinol / Cannabidiol (CBD oil)
B Substances > New (novel) psychoactive substances > Synthetic cannabinoids (Spice / K2 / OXIZID)
E Concepts in biomedical areas > Medical substance > Prescription drug (medicine / medication)
E Concepts in biomedical areas > Medical substance > Medical / medicinal cannabis
G Health and disease > State of health
J Health care, prevention, harm reduction and rehabilitation > Treatment and maintenance > Treatment issues (pain management)
J Health care, prevention, harm reduction and rehabilitation > Health care delivery
VA Geographic area > Europe > United Kingdom
Repository Staff Only: item control page